Navigation Links
Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer
Date:1/6/2009

AMSTERDAM, January 6 /PRNewswire/ -- Biopharmaceutical Company Kiadis Pharma focused on the development of innovative cell based therapeutics in the field of bone marrow transplantation, announces today the appointment of Dr. Maarten Egeler as Chief Medical Officer (CMO). Dr. Egeler is a global leading pediatric bone marrow transplantation physician and an internationally-recognized authority in pediatric hemato-oncology. He brings to Kiadis Pharma over more than 20 years of expertise in this field.

The appointment of Dr. Egeler is an important milestone in the development of Kiadis Pharma's lead product ATIR(TM) as a revolutionary approach to provide safe and potentially life-saving mismatched bone marrow transplantations as a treatment option for end-stage leukemia patients. Dr. Egeler's appointment will strongly support the upcoming multi-center pivotal study on ATIR(TM) early 2009.

Dr. Egeler will join Kiadis Pharma part time next to his position as Head of the Pediatric Oncology and Bone Marrow Transplantation division of the University of Leiden. As Kiadis Pharma's CMO, he will oversee all medical affairs of the company and he will work closely with the company's global network of key opinion leaders in the transplantation community on the development of the company's products.

"Maarten has been acting as a medical advisor for Kiadis Pharma over the last year and we are very pleased that he agreed to become our CMO", says Manja Bouman, CEO of Kiadis Pharma. "The depth of his medical expertise in the field of bone marrow transplantations, his leadership worldwide in haplo-identical transplantation and his network with key opinion leaders in the field will greatly contribute to the success of our products and company".

"I am very excited to join Kiadis Pharma in the role of CMO. I look forward to participate in the development of its programs. I am particularly excited to w
'/>"/>

SOURCE Kiadis Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
5. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
6. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
7. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
8. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
9. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... Today, Cryos International, the world’s largest international ... facilities and inventory from New York City to Orlando, ... relocation is a reflection of their increasing growth and ... completed during the first weekend of spring, March 21 ... April 6. The new facility in the Central Florida ...
(Date:3/30/2015)... , March 30, 2015  Multiple new research ... affect several important health factors. From their impact on ... their positive effect on both gut health and vascular ... (EB) detail our latest understanding of walnuts, inner workings. ... Boston , this annual meeting attracts an international ...
(Date:3/30/2015)... , March 30, 2015 CASI Pharmaceuticals, ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a commercial focus on ... and Drug Administration (CFDA) has approved the Company,s application ... ovarian clear cell carcinoma (OCCC) patients for its proprietary ...
(Date:3/30/2015)... England , March 30, 2015 ... developing novel biological drugs to treat cancer, viral ... of Professor Sir John Bell , the ... Chairman of the Office for the Strategic Coordination ... with immediate effect.      (Photo: ...
Breaking Biology Technology:Cryos International Completes Groundbreaking Sperm Migration to Orlando, Florida 2New Findings Support the Benefits of Eating Walnuts on Overall Health 2New Findings Support the Benefits of Eating Walnuts on Overall Health 3New Findings Support the Benefits of Eating Walnuts on Overall Health 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5
... Nov. 4 Dr. Juliet Singh,President and Chief Executive ... http://www.transdelpharma.com ), will present at,the Rodman & Renshaw Annual ... City. The Transdel presentation will be given in the,Kennedy ... on Tuesday, November 11th,at 2:25PM EST., To listen ...
... international pharmaceutical services group, reports that its,Functional Sourcing group ... force,for the current fiscal year, representing a continued trend ... growth has included:, -- Doubling the number ... pharmaceutical companies as ranked by Contract Pharma ...
... Children Reach Normal Height, PRINCETON, N.J., Nov. 4 ... from growing to a normal height now have a,new ... origin] injection) for the treatment of short stature in,children ... growth by,age 2-4 years., The U.S. Food and ...
Cached Biology Technology:Transdel Pharmaceuticals to Present at Rodman & Renshaw 10th Annual Global Healthcare Conference 2Premier Research Achieves Double-Digit Growth in Functional Sourcing for the Third Straight Year 2FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children 2FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children 3FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children 4FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children 5
(Date:3/10/2015)... , March 10, 2015  NXT-ID, Inc. (NASDAQ: ... the "Company"), a biometric authentication company focused on ... Wocket™ smart wallet has been named the "Number ... Modern. Rethink Modern ( http://www.rethinkmodern.com/ ) ... for your home and lifestyle that have a unique ...
(Date:3/3/2015)... FOREST, Calif. , March 3, 2015 ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, today announced the expansion ... Cancer Research Centers, ("Fred Hutch") Clinical ...
(Date:3/2/2015)... , March 2, 2015   Neurotechnology , ... today introduced the SentiGaze Software Development Kit ... create applications that use off-the-shelf webcams to track eye ... gazes at a monitor. Heatmaps can be used for ... effectiveness of online advertising. The SDK can also be ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... is available in German . Researchers today ... pumps, and thus specifically control them with light. The Gertrud ... 2012 to four scientists who initiated and were instrumental in ... of the Max Planck Institute of Biophysics in Frankfurt, Karl ...
... , A new fungal species, called , Hebelomagriseopruinatum , ... species. The fungus, whose name can be translated into ... Denmark during a mushroom-hunting tour headed by postdoc Jacob ... mushroom-hunting excursion in 2009, postdoc Jacob Heilman-Clausen from the ...
... In the face of mounting evidence that cancer cells ... and cancer researchers at Rice University, Tel Aviv University ... for outsmarting cancer through its own social intelligence. ... is a random collection of cells running amok," said ...
Cached Biology News:Zülch Prize 2012 for founders of optogenetics 2Zülch Prize 2012 for founders of optogenetics 3Zülch Prize 2012 for founders of optogenetics 4New Danish fungal species discovered 2Experts propose 'cyber war' on cancer 2Experts propose 'cyber war' on cancer 3
Immunogen: Synthetic peptide (KLH conjugated): L(506) S K S S S Q I R M S G L P A D N L A T(525) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
BD FastImmune EDTA Solution. Applications: Flow Cytometry Storage Temperature: Refrigerate(2 to 8C)...
... ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C 14 ... N O 6 ,M.W.= 408.63 ... Clear (2% in DMF) ,Biological Activity: ... M13 ,Elemental Analysis: Agrees with theoretical ...
Biology Products: